Amarin Corp Plc (AMRN)

[couldbebetter]

The number two question I have is what would AMRN be worth to Pfizer.
If Pfizer were to do an internal assessment of what they could do with
Vascepa if they owned AMRN. Could they sell enough Vascepa at a price
to make it worth their while? What would each major jurisdiction in
Europe be worth? China? (If an approval ever comes.) The UK? (If
the team there didn't already blow it.) Perhaps even the US (One
estimate with a Du reversal and one estimate as an authorized generic.)
Of course there is the rest of the world. (Wherever Pfizer believes
they would have an advantage.)

Next, would Pfizer support research (in Europe) for new indications.
(At least those where studies would be easily completed for things
like dry eyes or maybe as an adjunct for certain cancers.)

Then, would Pfizer want to integrate Mochida's one a day version?
(Maybe they would want to buy Mochida.)

How well does Pfizer understand the science? Could they get ineffective
Omega-3' such as generic Lovasa pulled off the market? Could they
convince the US consumer that OTC fish oils may be rancid and/or
ineffective? Hopefully, Denner has already has the answers.